NCT07659574 UBT-251 Diabetes Mellitus, Type 2 Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook

Turn a newly registered trial into a decision-ready landscape. This focused report examines NCT07659574—Phase III Study of UBT251 Injection in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Diet and Exercise Alone（UNIGUIDE-1） (UNIGUIDE-1)—using PatSnap Clinical Trials MCP for protocol design and endpoint evidence, Drug & Asset MCP for mechanism and development context, and Company & Deal Intelligence MCP for sponsor background. Explore PatSnap MCP Servers to reproduce the workflow inside an AI research process.

MCP evidence snapshot: 20 July 2026; publication date: 20 July 2026. Trial records can change after the snapshot and should be rechecked before operational decisions.

Why NCT07659574 is a hot trial to watch

Diabetes Mellitus, Type 2 is increasingly segmented by mechanism, biomarker, treatment setting, geography and endpoint architecture. NCT07659574 is notable because it evaluates UBT-251 in a Phase 3 design while Change in HbA1c from Baseline serves as the main decision variable. The critical question is whether the protocol can convert its rationale into a clinically interpretable and operationally credible readout.

PatSnap Clinical Trials MCP makes protocol fields machine-readable, while the companion asset and organization servers add development-status, target and sponsor context.

Trial landscape snapshot

Design and endpoint interpretation

The phase label is only the starting point. Allocation is Randomized, masking is Triple, and the intervention model is Parallel Assignment. Planned enrollment of 360 participants across China shapes statistical precision, execution risk and external validity. Interpretation should account for baseline risk, prior therapy, assessment schedule, missing-data handling and clinical relevance—not only statistical significance.

• Primary: Change in HbA1c from Baseline (Week 36)
• Secondary: Proportion of participants with HbA1c \<7.0%，HbA1c ≤6.5% and \<5.7 from baseline (Week 36)
• Secondary: Percent change in body weight from baseline (Week 36)
• Secondary: Proportion of participants with body weight reduction ≥5% from baseline (Week 36)
• Secondary: Proportion of trial participants with HbA1c \<7.0% and body weight reduction ≥5% from baseline (Week 36)

Benchmark readouts in the surrounding field

• The Effect of Tirzepatide Versus Dulaglutide on Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes (SURPASS-CVOT) (Phase 3): Number of Participants From Randomization to First Occurrence of Death From MACE-3 [Composite Endpoint of Major Adverse Cardiovascular Events Death From Cardiovascular Causes, Myocardial Infarction (MI) or Stroke] = 801 participants ; Number of Participants From Randomization to First Occurrence of Death From MACE-3 [Composite Endpoint of Major Adverse Cardiovascular Events Death From Cardiovascular Causes, Myocardial Infarction (MI) or Stroke] = 862 participants
• A Study to Evaluate the Efficacy and Safety of Once-weekly Insulin Icodec When Switching From Daily Basal Insulins Compared to Once-daily Insulin Glargine U100 in Adults With Type 2 Diabetes (Phase 3): Change in Glycated Haemoglobin (HbA1c)(Mean) = -0.84 Percentage (%) point (Standard Deviation, 0.83); Change in Glycated Haemoglobin (HbA1c)(Mean): Treatment difference = -0.21(95% CI, -0.36 to -0.07), P-Value = <0.0001
• A Phase 3, Long-term Safety Study of LY3502970 in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone or in Combination With Oral Antihyperglycemic Medications (ACHIEVE-J) (Phase 3): Number of Participants With Treatment Emergent Adverse Events (TEAEs) = 114 Participants ; Number of Participants With Treatment Emergent Adverse Events (TEAEs) = 107 Participants

These indexed results are contextual benchmarks, not direct head-to-head evidence. Population, treatment line, endpoint definitions, follow-up and analysis sets may differ. Their value is to clarify the type and magnitude of evidence already visible in the competitive landscape.

Build a living trial monitor: connect to PatSnap MCP Servers and track status changes, endpoint revisions, primary-completion dates and newly indexed results without manually reconciling separate databases.

Asset and sponsor context

Drug & Asset context: UBT-251 (Phase 3; GCGR x GIPR x GLP-1R)

Company & Deal Intelligence context: The United Bio-Technology(Hengqin) Co., Ltd. — China

The sponsor profile matters because scientific rationale alone does not determine development value. Manufacturing readiness, portfolio fit, geographic reach, partnering capacity and the ability to fund confirmatory development can decide whether a positive signal becomes a competitive asset.

White space around this program

• Sharper patient selection: prospective biomarker or phenotype definitions that identify who is most likely to benefit.
• Clinically interpretable endpoints: outcomes connecting activity with function, symptoms, survival or treatment burden.
• Sequencing evidence: comparative data after the most relevant contemporary standard of care.
• Broader external validity: evidence across additional geographies, demographic groups and real-world settings.
• Operational differentiation: a development path that closes the readout gap without sacrificing safety or durability.

What to monitor next

Monitor recruitment, enrollment changes, protocol amendments, endpoint hierarchy, primary-completion timing, first result indexing, asset ownership and sponsor partnerships. A change in endpoint, population or ownership can alter probability of success before a headline data release.

Bottom line

NCT07659574 is a focused lens on Diabetes Mellitus, Type 2 development. Its value will be determined by whether UBT-251 can convert the current design into evidence that is clinically meaningful, operationally credible and differentiated from indexed benchmark readouts.

Ready to reproduce this analysis? Explore PatSnap MCP Servers and combine Clinical Trials, Drug & Asset, and Company & Deal Intelligence as reusable building blocks for trial monitoring and SEO-ready clinical reports.